Serum adropin levels are reduced in patients with inflammatory bowel diseases
Abstract Adropin is a novel peptide mostly associated with energy homeostasis and vascular protection. To our knowledge, there are no studies that investigated its relationship with inflammatory bowel diseases (IBD). The aim of this study was to compare serum adropin levels between 55 patients with...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2020-06-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-020-66254-9 |
| _version_ | 1818435090636603392 |
|---|---|
| author | Darko Brnić Dinko Martinovic Piero Marin Zivkovic Daria Tokic Ivana Tadin Hadjina Doris Rusic Marino Vilovic Daniela Supe-Domic Ante Tonkic Josko Bozic |
| author_facet | Darko Brnić Dinko Martinovic Piero Marin Zivkovic Daria Tokic Ivana Tadin Hadjina Doris Rusic Marino Vilovic Daniela Supe-Domic Ante Tonkic Josko Bozic |
| author_sort | Darko Brnić |
| collection | DOAJ |
| description | Abstract Adropin is a novel peptide mostly associated with energy homeostasis and vascular protection. To our knowledge, there are no studies that investigated its relationship with inflammatory bowel diseases (IBD). The aim of this study was to compare serum adropin levels between 55 patients with IBD (30 Ulcerative colitis (UC) patients, 25 Crohn’s disease (CD) patients) and 50 age/gender matched controls. Furthermore, we explored adropin correlations with IBD severity scores, hsCRP, fecal calprotectin, fasting glucose and insulin levels. Serum adropin levels were significantly lower in patients with IBD in comparison with the control group (2.89 ± 0.94 vs 3.37 ± 0.60 ng/mL, P = 0.002), while there was no significant difference in comparison of UC patients with CD patients (P = 0.585). Furthermore, there was a negative correlation between adropin and fecal calprotectin (r = −0.303, P = 0.025), whereas in the total study population, we found a significant negative correlation with fasting glucose levels (r = −0.222, P = 0.023). A multivariable logistic regression showed that serum adropin was a significant predictor of positive IBD status when enumerated along with baseline characteristics (OR 0.455, 95% CI 0.251–0.823, P = 0.009). Our findings imply that adropin could be involved in complex pathophysiology of IBD, but further larger scale studies are needed to address these findings. |
| first_indexed | 2024-12-14T16:47:21Z |
| format | Article |
| id | doaj.art-f88028686be6416dbea14b895faee203 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-14T16:47:21Z |
| publishDate | 2020-06-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-f88028686be6416dbea14b895faee2032022-12-21T22:54:10ZengNature PortfolioScientific Reports2045-23222020-06-011011910.1038/s41598-020-66254-9Serum adropin levels are reduced in patients with inflammatory bowel diseasesDarko Brnić0Dinko Martinovic1Piero Marin Zivkovic2Daria Tokic3Ivana Tadin Hadjina4Doris Rusic5Marino Vilovic6Daniela Supe-Domic7Ante Tonkic8Josko Bozic9Department of Gastroenterology, University Hospital of SplitInstitute of Emergency Medicine of Split-Dalmatia CountyDepartment of Gastroenterology, University Hospital of SplitInstitute of Emergency Medicine of Split-Dalmatia CountyDepartment of Gastroenterology, University Hospital of SplitDepartment of Pharmacy, University of Split School of MedicineDepartment of Pathophysiology, University of Split School of MedicineDepartment of Medical Laboratory Diagnostics, University Hospital of SplitDepartment of Gastroenterology, University Hospital of SplitDepartment of Pathophysiology, University of Split School of MedicineAbstract Adropin is a novel peptide mostly associated with energy homeostasis and vascular protection. To our knowledge, there are no studies that investigated its relationship with inflammatory bowel diseases (IBD). The aim of this study was to compare serum adropin levels between 55 patients with IBD (30 Ulcerative colitis (UC) patients, 25 Crohn’s disease (CD) patients) and 50 age/gender matched controls. Furthermore, we explored adropin correlations with IBD severity scores, hsCRP, fecal calprotectin, fasting glucose and insulin levels. Serum adropin levels were significantly lower in patients with IBD in comparison with the control group (2.89 ± 0.94 vs 3.37 ± 0.60 ng/mL, P = 0.002), while there was no significant difference in comparison of UC patients with CD patients (P = 0.585). Furthermore, there was a negative correlation between adropin and fecal calprotectin (r = −0.303, P = 0.025), whereas in the total study population, we found a significant negative correlation with fasting glucose levels (r = −0.222, P = 0.023). A multivariable logistic regression showed that serum adropin was a significant predictor of positive IBD status when enumerated along with baseline characteristics (OR 0.455, 95% CI 0.251–0.823, P = 0.009). Our findings imply that adropin could be involved in complex pathophysiology of IBD, but further larger scale studies are needed to address these findings.https://doi.org/10.1038/s41598-020-66254-9 |
| spellingShingle | Darko Brnić Dinko Martinovic Piero Marin Zivkovic Daria Tokic Ivana Tadin Hadjina Doris Rusic Marino Vilovic Daniela Supe-Domic Ante Tonkic Josko Bozic Serum adropin levels are reduced in patients with inflammatory bowel diseases Scientific Reports |
| title | Serum adropin levels are reduced in patients with inflammatory bowel diseases |
| title_full | Serum adropin levels are reduced in patients with inflammatory bowel diseases |
| title_fullStr | Serum adropin levels are reduced in patients with inflammatory bowel diseases |
| title_full_unstemmed | Serum adropin levels are reduced in patients with inflammatory bowel diseases |
| title_short | Serum adropin levels are reduced in patients with inflammatory bowel diseases |
| title_sort | serum adropin levels are reduced in patients with inflammatory bowel diseases |
| url | https://doi.org/10.1038/s41598-020-66254-9 |
| work_keys_str_mv | AT darkobrnic serumadropinlevelsarereducedinpatientswithinflammatoryboweldiseases AT dinkomartinovic serumadropinlevelsarereducedinpatientswithinflammatoryboweldiseases AT pieromarinzivkovic serumadropinlevelsarereducedinpatientswithinflammatoryboweldiseases AT dariatokic serumadropinlevelsarereducedinpatientswithinflammatoryboweldiseases AT ivanatadinhadjina serumadropinlevelsarereducedinpatientswithinflammatoryboweldiseases AT dorisrusic serumadropinlevelsarereducedinpatientswithinflammatoryboweldiseases AT marinovilovic serumadropinlevelsarereducedinpatientswithinflammatoryboweldiseases AT danielasupedomic serumadropinlevelsarereducedinpatientswithinflammatoryboweldiseases AT antetonkic serumadropinlevelsarereducedinpatientswithinflammatoryboweldiseases AT joskobozic serumadropinlevelsarereducedinpatientswithinflammatoryboweldiseases |